Oncology Institute holder buys 25K shares

Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction.

Rhea-AI Filing Summary

Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction. The weighted average purchase price was about $3.35 per share, with individual trades between $3.33 and $3.35.

After this purchase, Chernett directly owns 10,276,929 Oncology Institute shares.

Insider Trade Summary

Net Buyer: 25,000 shares

Net Buy 1 txn

Insider Chernett Jorey

Role 10% Owner

Bought 25,000 shs ($84K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25,000	$3.35	$84K

Holdings After Transaction: Common Stock — 10,276,929 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.35, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

FAQ

What insider transaction did Jorey Chernett report for TOI?

Jorey Chernett reported an open-market purchase of Oncology Institute common stock. He bought 25,000 shares, expanding an already large position. The transaction reflects a net increase in his direct holdings, according to the Form 4 data.

How many Oncology Institute (TOI) shares did Chernett buy and at what price?

Chernett purchased 25,000 shares of Oncology Institute common stock. The weighted average price was about $3.35 per share, with individual trades executed between $3.33 and $3.35, all rounded to the nearest cent, as disclosed.

What are Jorey Chernett’s total TOI holdings after this transaction?

After the reported purchase, Jorey Chernett directly owns 10,276,929 shares of Oncology Institute common stock. This figure represents his direct beneficial ownership following the 25,000-share open-market acquisition reported on the Form 4.

Was the TOI insider transaction a purchase or a sale?

The TOI insider transaction was a purchase, not a sale. The Form 4 shows transaction code “P” and describes it as an open-market purchase, resulting in a net buy of 25,000 Oncology Institute common shares for Jorey Chernett.

What does the Form 4 footnote say about Chernett’s TOI trade prices?

The footnote explains the reported price is a weighted average rounded to the nearest cent. It states the 25,000 shares were bought in multiple trades at prices ranging from $3.33 to $3.35 per share, and detailed breakdowns are available on request.

Is Jorey Chernett considered a major shareholder of Oncology Institute (TOI)?

Yes. The Form 4 identifies Jorey Chernett as a ten percent owner of Oncology Institute. After the purchase, he directly owns 10,276,929 common shares, indicating a significant stake relative to typical individual investors in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 09:33 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernett Jorey

(Last) (First) (Middle)

6222 INDIANWOOD TR.

(Street)

BLOOMFIELD HILLS MICHIGAN 48301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		P		25,000	A	$3.35(1)	10,276,929	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.35, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

	/s/ Jorey Chernett	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)